Active substance |
Delta-1,4,9(11)-pregnatriene-17,21-dihydroxy-16-alpha-methyl-3,20- dione |
Holder |
Santhera Pharmaceuticals (Switzerland) |
Status |
Running |
Indication |
Duchenne Muscular Dystrophy in boys who are completing the VBP15-004 trial |
Public documents |
|
Last update |
23/052023 |
Vamorolone
Last updated on 13/02/2024